Review of Asprosin as new Biomarker for diagnosis different Diseases


  • safaa ehssan National diabetes center mustansiriyah university
  • Baydaa Ahmed Abed
  • Isam Noori Salman
  • Lujain A. Ghannawi



asprosin, Diabetes Mellitus type2, cardiovascular, FBN1, Obesity


This study was designed to investigate the connections between (Inflammation, Cardiovascular diseases (CVDs),-diabetes mellitus,-Obesity,-polycystic ovary syndrome, thyroid and cancer )-and asprosin hormone. Asprosin is present in high amounts in a variety of diseases that are considerably manifested in several cases and illnesses Asprosin hormone is newly adipokine helps the liver produce glucose. White adipose tissue secretes the novel hormone asprosin, which stimulates the release of hepatic glucose, making protein a possible target for new treatments for obesity and  type 2 diabetes mellitus. Exons (65 and 66) of the gene( Fibrillin 1 (FBN1)), which was recently shown to be a new hormone released by white adipose tissues, are the final two exons that code for asprosin. However, further research is needed to fully understand how asprosin affects pancreatic beta-cells, leading to pathologically elevated cellular dysfunction and inflammation. Asprosin hormone is raised  in human  with metabolic disease. The findings imply that asprosin hormone  may be crucial for maintaining insulin and glucose homeostasis as well as acting as a risk factor for a number of diseases, including CVDs, obesity,  T2DM, cancer, hypothyroidism, and PCOS. Depleting asprosin or attenuating its activity may potentially offer a novel therapeutic option for the treatment of T2DM and obesity.


N. Ateah, A. Y. Abed, and B. A. Abed, "Evaluation of Asprosin Hormone in Hypothyroidism Patients," Ibn AL-Haitham Journal For Pure and Applied Sciences, vol. 36, no. 2, pp. 224-231, 2023.

L. Lönnqvist, D. Reinhardt, L. Sakai, and L. Peltonen, "Evidence for furin-type activity-mediated C-terminal processing of profibrillin-1 and interference in the processing by certain mutations," Human molecular genetics, vol. 7, no. 13, pp. 2039-2044, 1998.

C. Duerrschmid et al., "Asprosin is a centrally acting orexigenic hormone," Nature medicine, vol. 23, no. 12, pp. 1444-1453, 2017.

M. R. Davis et al., "Datasets of genes coexpressed with FBN1 in mouse adipose tissue and during human adipogenesis," Data in brief, vol. 8, pp. 851-857, 2016.

C. Romere et al., "Asprosin, a fasting-induced glucogenic protein hormone," Cell, vol. 165, no. 3, pp. 566-579, 2016.

M. Yuan, W. Li, Y. Zhu, B. Yu, and J. Wu, "Asprosin: a novel player in metabolic diseases," Frontiers in endocrinology, vol. 11, p. 64, 2020.

J. G. Hoffmann, W. Xie, and A. R. Chopra, "Energy regulation mechanism and therapeutic potential of asprosin," Diabetes, vol. 69, no. 4, pp. 559-566, 2020.

M. Farrag et al., "Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects," Frontiers in Endocrinology, vol. 13, p. 1101091, 2023.

J. Montane, L. Cadavez, and A. Novials, "Stress and the inflammatory process: a major cause of pancreatic cell death in type 2 diabetes," Diabetes, metabolic syndrome and obesity: targets and therapy, pp. 25-34, 2014.

D. H. van Raalte and M. Diamant, "Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?," Diabetes research and clinical practice, vol. 93, pp. S37-S46, 2011.

T. Lee, S. Yun, J. H. Jeong, and T. W. Jung, "Asprosin impairs insulin secretion in response to glucose and viability through TLR4/JNK-mediated inflammation," Molecular and cellular endocrinology, vol. 486, pp. 96-104, 2019.

G. A. Roth et al., "Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study," Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2982-3021, 2020.

L. Zhang, C. Chen, N. Zhou, Y. Fu, and X. Cheng, "Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride," Clinica chimica acta, vol. 489, pp. 183-188, 2019.

M.-S. Wen et al., "The role of Asprosin in patients with dilated cardiomyopathy," BMC Cardiovascular Disorders, vol. 20, no. 1, pp. 1-8, 2020.

W. H.-h. L. Wan-ying1Lin, M. L. X.-j. X. Guang-da, and S. d Triganti, "page (Original article)."

L. J. McCulloch, L. R. Bramwell, B. Knight, and K. Kos, "Circulating and tissue specific transcription of angiopoietin-like protein 4 in human Type 2 diabetes," Metabolism, vol. 106, p. 154192, 2020.

W. Hao-Hua, L. Wan-Ying, L. Min, L. Xiao-Jing, G.-D. Xiang, and S. D TRIGANTI, "Plasma asprosin, CCDC80 and ANGPTL4 levels are associated with metabolic and cardiovascular risk in patients with inflammatory bowel disease," Physiological Research, vol. 70, no. 2, p. 203, 2021.

Z. Zhang, L. Zhu, Z. Wang, N. Hua, S. Hu, and Y. Chen, "Can the new adipokine asprosin be a metabolic troublemaker for cardiovascular diseases? A state-of-the-art review," Progress in Lipid Research, vol. 91, p. 101240, 2023.

L. Liu et al., "The effects of asprosin on exercise-intervention in metabolic diseases," Frontiers in physiology, vol. 13, p. 907358, 2022.

X. Zhang, H. Jiang, X. Ma, and H. Wu, "Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus," Journal of diabetes investigation, vol. 11, no. 2, pp. 349-355, 2020.

X. Li et al., "Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases," Mediators of inflammation, vol. 2018, 2018.

Y. Wang et al., "Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion," Mediators of inflammation, vol. 2018, 2018.


A. Elnagar, H. I. El-Belbasi, I. F. Rehan, and K. El-Dawy, "Asprosin: a novel biomarker of type 2 diabetes mellitus," Veterinary medicine in-between health & economy, vol. 55, no. 20, pp. 333-347, 2018.

D. Corica et al., "Asprosin serum levels and glucose homeostasis in children with obesity," Cytokine, vol. 142, p. 155477, 2021.

Y. Miao, H. Qin, Y. Zhong, K. Huang, and C. Rao, "Novel adipokine asprosin modulates browning and adipogenesis in white adipose tissue," The Journal of endocrinology, vol. 249, no. 2, p. 83, 2021.

H. Nakhaei, M. Mogharnasi, and H. Fanaei, "Effect of swimming training on levels of asprosin, lipid profile, glucose and insulin resistance in rats with metabolic syndrome," Obesity medicine, vol. 15, p. 100111, 2019.

R. Mogulkoc, D. Dasdelen, S. B. Baltaci, A. K. Baltaci, and A. Sivrikaya, "The effect of thyroid dysfunction and treatment on adropin, asprosin and preptin levels in rats," Hormone Molecular Biology and Clinical Investigation, vol. 42, no. 1, pp. 37-42, 2020.

M. Kantorowicz, J. Szymura, Z. Szygula, J. Kusmierczyk, M. Maciejczyk, and M. Wiecek, "Nordic walking at maximal fat oxidation intensity decreases circulating asprosin and visceral obesity in women with metabolic disorders," Frontiers in Physiology, vol. 12, p. 726783, 2021.

L. H. Al-Sultan and Y. A. Al-Issa, "Estimation of adropin hormone in Iraqi hypothyroidism patients with obesity," Acta Biomed, vol. 94, no. 2, p. e2023100, 2023.

R. Deniz et al., "Subfatin and asprosin, two new metabolic players of polycystic ovary syndrome," Journal of Obstetrics and Gynaecology, vol. 41, no. 2, pp. 279-284, 2021.

F. R. Pérez-López, M. T. López-Baena, G. R. Pérez-Roncero, P. Chedraui, S. R. Varikasuvu, and P. García-Alfaro, "Asprosin levels in women with and without the polycystic ovary syndrome: a systematic review and meta-analysis," Gynecological Endocrinology, vol. 39, no. 1, p. 2152790, 2023.

C.-W. Hsu et al., "Association between malignancies and Marfan syndrome: a population-based, nested case–control study in Taiwan," BMJ open, vol. 7, no. 10, p. e017243, 2017.

S. E. ATTA and E. D. SALMAN, "Molecular Study of Fluoroquinolones Resistance Staphylococcus Aureus Isolated from Different Clinical Sources," International Journal of Pharmaceutical Research (09752366), vol. 12, no. 3, 2020.

K. M. Summers et al., "Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1," Genomics, vol. 94, no. 4, pp. 233-240, 2009.

J. Millstein et al., "Prognostic gene expression signature for high-grade serous ovarian cancer," Annals of Oncology, vol. 31, no. 9, pp. 1240-1250, 2020.

R. Kerslake et al., "A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer," Oncology letters, vol. 22, no. 3, pp. 1-14, 2021.

T. W. Jung et al., "Asprosin attenuates insulin signaling pathway through PKCδ‐activated ER stress and inflammation in skeletal muscle," Journal of cellular physiology, vol. 234, no. 11, pp. 20888-20899, 2019.

E. Li et al., "OLFR734 mediates glucose metabolism as a receptor of asprosin," Cell metabolism, vol. 30, no. 2, pp. 319-328. e8, 2019.

M. M. Aboudounya and R. J. Heads, "COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation," Mediators of inflammation, vol. 2021, pp. 1-18, 2021.

Y. Lin, M. Jiang, W. Chen, T. Zhao, and Y. Wei, "Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response," Biomedicine & Pharmacotherapy, vol. 118, p. 109249, 2019.

N. A. Lefta, A. Y. Abed, and B. A. Abed, "Estimation of Asprosin Levels in Female Iraqi Patients with Type 2 Diabetes and Hypothyroidism," Journal of Medicinal and Chemical Sciences, vol. 6, no. 2, pp. 433-439, 2023, doi: 10.26655/jmchemsci.2023.2.23.




How to Cite

Review of Asprosin as new Biomarker for diagnosis different Diseases. (2023). University of Thi-Qar Journal of Science, 10(2), 160-164.